HRT Boxed Warnings Removed: How OB/GYNs Should Counsel Now

HRT boxed warnings on cardiovascular, breast cancer, and dementia risk are off most menopausal hormone therapy labels in 2026. The shift changes how OB/GYNs counsel and document consent.

April 26, 2026 · 4 min read

Why HRT Boxed Warnings Are in the News Right Now

HRT boxed warnings on cardiovascular disease, breast cancer, and probable dementia were removed from six menopausal hormone therapy products on February 12, 2026, the U.S. Food and Drug Administration (FDA) announced. The labeling change is the first batch of revisions affecting all four HRT product categories: systemic combination therapy (estrogen and progestogen), systemic estrogen-alone therapy, systemic progestogen-alone therapy, and topical vaginal estrogen.

The action followed a public expert panel in July 2025, an HHS announcement in November 2025, and a public comment period. At the FDA’s request, 29 drug companies have submitted proposed labeling changes; more product updates are expected. The agency kept the boxed warning for endometrial cancer on systemic estrogen-alone products in patients with a uterus.

Patient interest surged after the announcement, and many patients are asking their OB/GYNs whether systemic estrogen — long carried in the same boxed warning as low-dose vaginal estrogen — is now considered safer for them than they were previously told.

The Background of HRT Boxed Warnings

The HRT boxed warnings traced back to early results from the Women’s Health Initiative (WHI), a randomized controlled trial halted in July 2002 because of an increase in breast cancer and cardiovascular events in the combined estrogen-progestin arm. WHI participants averaged 63 years of age, and most used conjugated equine estrogens with medroxyprogesterone acetate.

The 2003 boxed warning applied uniformly across all systemic and vaginal estrogen products, regardless of dose, route, or formulation. HRT use plummeted in the years that followed. In 2020, only about 2 million of the 41 million U.S. women aged 45 to 64 received an HRT prescription, according to FDA figures.

The Evidence So Far

Reanalyses of WHI and subsequent age-stratified data narrowed the picture. The “timing hypothesis” emerged: women who initiate HRT within 10 years of menopause onset, generally before age 60, appear to face a different benefit-risk profile than those starting later.

Mortality: Women starting HRT before age 60 had a reduced risk of all-cause mortality, FDA cited
Vasomotor symptoms: Symptom relief is well-established for moderate to severe hot flashes and night sweats
Dementia signal: The probable-dementia finding came from women older than 65 — outside the typical initiation age (45–55)
Vaginal estrogen: Low-dose vaginal estrogen has minimal systemic absorption and a different safety profile than oral or transdermal HRT
Endometrial cancer: Boxed warning retained for systemic estrogen-alone products in women with a uterus

FDA’s updated systemic HRT labels now emphasize initiation within 10 years of menopause onset or before age 60.

Where Experts Disagree

The American College of Obstetricians and Gynecologists (ACOG) supported the change as removing a longstanding barrier to low-dose vaginal estrogen prescribing but explicitly distinguished it from systemic therapy. ACOG noted that systemic estrogen products:

“have a different safety profile than low-dose vaginal estrogen” — ACOG Statement, November 10, 2025

The Menopause Society endorsed the vaginal estrogen change while cautioning that systemic estrogen still carries individualized risks warranting detailed counseling at initiation. Breast oncologists at the San Antonio Breast Cancer Symposium urged that for patients with a personal or family history of breast cancer, the decision remains nuanced because recurrence risk varies by tumor biology. Some commentators have also questioned the process, arguing that systemic HRT label changes typically follow a more extensive and transparent regulatory review.

The Practical Question for OB/GYNs

For OB/GYNs, the change shifts the consent conversation from a binary “FDA-warned, high risk” frame to a more nuanced one — but does not eliminate the need for individualized risk assessment. ACOG has stated that the announcement does not change its existing guidance to counsel patients based on each individual’s risk factors and treatment goals.

A practical counseling checklist:

Indication: Vasomotor symptoms, genitourinary syndrome of menopause, or osteoporosis prevention
Timing: Shared decision-making favors initiation within 10 years of menopause onset or before age 60 for systemic HRT
Individual risk: Personal and family history of breast cancer, cardiovascular disease, venous thromboembolism, and migraine with aura
Formulation: Low-dose vaginal estrogen has minimal systemic absorption; systemic estrogen carries risks regardless of label changes
Compounded products: ACOG continues to recommend against compounded estrogen, which is not subject to the FDA labeling action

Documentation should record formulation, indication, timing relative to menopause onset, and that benefits and individualized risks were discussed.

What to Watch For

Additional HRT boxed warnings updates as the remaining ~23 products move through FDA review
Updated ACOG and Menopause Society guidance reflecting the new labels
Real-world prescribing data and adverse-event signals after February 12, 2026
Insurance and Medicare Part D coverage adjustments for relabeled products
Pregnancy and post-marketing safety reports under the new regulatory frame

Sources

U.S. Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. Press release, February 12, 2026. FDA Announcement on First Batch of HRT Label Changes
U.S. Department of Health and Human Services. FACT SHEET: FDA Initiates Removal of “Black Box” Warnings from Menopausal Hormone Replacement Therapy Products. November 10, 2025. HHS Fact Sheet on HRT Boxed Warning Removal
American College of Obstetricians and Gynecologists. ACOG President Says Label Change on Estrogen Will Increase Access to Hormone Therapy. News release, November 10, 2025. ACOG Statement on FDA HRT Label Change
The Menopause Society. The Menopause Society Comments on the FDA Announcement on Hormone Therapy. November 14, 2025. The Menopause Society Statement on FDA Action
Makary MA, Nguyen CP, Høeg TB, Tidmarsh GF. Updated labeling for menopausal hormone therapy. JAMA. 2026;335(2):117–118. JAMA Viewpoint by FDA Leadership on Updated HRT Labeling
U.S. Food and Drug Administration. Menopausal Hormone Therapies with Updated Prescribing Information. February 2026. FDA Index of Updated Menopausal Hormone Therapy Labels
Society of Gynecologic Oncology. FDA Removes Black-Box Warnings on Hormone Replacement Therapy. November 2025. SGO Member Briefing on Endometrial Cancer Warning Retention